[Featured Stock] HLB Rises 4% on News of Reapplying for US Approval of Liver Cancer Drug

HLB, which has entered the FDA re-evaluation process for Rivoceranib (product name Tulbezio), developed as a first-line treatment for liver cancer, is showing strong performance.

As of 9:57 AM on the 9th, HLB is trading at 88,900 KRW, up 4.10% (3,500 KRW) from the previous trading day. The news that HLB is re-challenging FDA approval for the first-line liver cancer treatment appears to have acted as a positive factor.

According to the pharmaceutical industry, HLB will submit documents related to FDA approval for Rivoceranib as a first-line liver cancer treatment by the 20th. HLB aims to receive approval for the first-line liver cancer treatment using a combination therapy of Rivoceranib and Camrelizumab, an immuno-oncology drug developed by China’s Hansoh Pharmaceutical.

Previously, HLB’s stock price plummeted after failing to obtain FDA approval for Rivoceranib, and its transfer listing to KOSPI was also postponed.